
AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer PMLiVE
AstraZeneca’s Imfinzi is the latest PD-1/PD-L1 inhibitor to show clinical activity in small cell lung cancer (SCLC), extending survival when used as a first-line …
“bladder cancer” – Google News
